Hong Kong stocks concept tracking | U.S. to relax marijuana regulations Industrial chain companies may see a turning point (with concept stocks)

The Department of Justice in the United States announced on Thursday that it will immediately relax restrictions on some marijuana products and take swift action to reclassify marijuana as a less dangerous drug, marking one of the biggest changes in U.S. drug policy in decades. This move will not legalize marijuana nationwide, but it is likely to reshape the $47 billion industry. Despite most states in the U.S. having legalized marijuana in some form for medical purposes, and nearly half of the states legalizing it for recreational use, the industry still faces significant obstacles at the federal level. Now, medical marijuana products regulated by states will be moved from the category of highly addictive drugs like heroin to a category with fewer restrictions, with products having a lower to moderate potential for abuse, such as common painkillers, ketamine, and testosterone. FDA-approved marijuana products will also fall into this category. Related concepts of U.S. marijuana policy in the stock market include: - JIA YAO HLDGS (01626): announced that the group has been focusing on the health and biopharmaceutical sectors in recent years. The group officially launched CBD-related business in April 2026. Currently, the group mainly engages in purchasing CBD from China and exporting it to skincare, cosmetics, and pharmaceutical companies in Europe and North America. The group has established a dedicated operations team for this business, with core members having relevant industry experience. - SMOORE INTL (06969): the company's clients include multinational tobacco groups such as Japan Tobacco, British American Tobacco, Reynolds Asia-Pacific, RELX, and NJOY, as well as leading global e-cigarette companies. As a leader in the CBD industry, the company will benefit from the growth of the legalized marijuana market; the company will actively develop customers in the medical and healthcare fields in the future, innovate drug delivery methods, and apply them to treat diseases such as asthma and COPD.